Unknown

Dataset Information

0

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab.


ABSTRACT: Purpose:Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment of metastatic colorectal cancer. Molecular predictors of B efficacy have still not been identified. We analyzed the role of 22 angiogenesis-associated proteins in patient outcome. Patients and methods:Serum samples collected at baseline and at the first clinical evaluation were available for 58 patients enrolled in the randomized multicenter ITACa trial and who received CT+ B. Serum protein levels were determined using multiplex ELISA. Results:Patients with baseline ?145 pg/mL IL-8 showed shorter median progression-free survival and overall survival (OS) than those with lower levels (6.5 vs 6. 12.6 months; HR 7.39, P<0.0001 and 8.7 vs 28.8 months, HR 7.68, P<0.001, respectively). Moreover, patients with baseline thrombospondin-1 levels ?12,000 ng/mL had a better median OS than those with lower levels (34.5 vs 13.1 months, HR 0.43, P=0.007). Patients with a ?20% reduction in IL-8 levels from baseline to first clinical evaluation showed a better progression-free survival and OS than the others (HR 0.41, P=0.005 and HR 0.43, P=0.007, respectively). Conclusion:Baseline IL-8 and thrombospondin-1 levels and reduced IL-8 during B treatment could represent potential prognostic markers in metastatic colorectal cancer.

SUBMITTER: Marisi G 

PROVIDER: S-EPMC6241685 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab.

Marisi Giorgia G   Scarpi Emanuela E   Passardi Alessandro A   Nanni Oriana O   Pagan Flavia F   Valgiusti Martina M   Casadei Gardini Andrea A   Neri Luca Maria LM   Frassineti Giovanni Luca GL   Amadori Dino D   Ulivi Paola P  

Cancer management and research 20181114


<h4>Purpose</h4>Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment of metastatic colorectal cancer. Molecular predictors of B efficacy have still not been identified. We analyzed the role of 22 angiogenesis-associated proteins in patient outcome.<h4>Patients and methods</h4>Serum samples collected at baseline and at the first clinical evaluation were available for 58 patients enrolled in the randomized multicenter <i>ITACa</i> trial and who received CT+ B. Serum p  ...[more]

Similar Datasets

| S-EPMC7806753 | biostudies-literature
| S-EPMC4419077 | biostudies-literature
| S-EPMC6110978 | biostudies-literature
| S-EPMC6173768 | biostudies-literature
| S-EPMC7059922 | biostudies-literature
| S-EPMC5431064 | biostudies-literature
| S-EPMC5833618 | biostudies-literature
| S-EPMC8456503 | biostudies-literature
| S-EPMC3639662 | biostudies-literature
| S-EPMC4893985 | biostudies-literature